XBiotech Inc.

$2.44

+$0.06 (+2.52%)

Jan 5, 2026

Price History (1Y)

Analysis

XBiotech Inc. is a biotechnology company in the healthcare sector with a market capitalization of $74.39M. It has 88 employees. The company's financial health is characterized by significant losses, with net income and EBITDA both totaling -$29.2 million and -$32.9 million, respectively. Free cash flow was -$18.5 million. Gross margin, operating margin, and profit margin were all at 0%. Return on equity (ROE) was -16.2%, while return on assets (ROA) was -11.3%. XBiotech Inc.'s valuation metrics include a forward P/E ratio of 18.77 and an EV/EBITDA of 2.22. The company's price to book ratio is 0.45, and its cash balance is $147.37 million.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About XBiotech Inc.

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Visit website →

Key Statistics

Market Cap
$74.39M
P/E Ratio
N/A
52-Week High
$4.54
52-Week Low
$2.09
Avg Volume
103.23K
Beta
0.80

Company Info

Exchange
NMS
Country
United States
Employees
88